In addition to glycemic control, SGLT2 inhibitors can also lower body weight and blood pressure and reduce relevant adverse cardiovascular consequnces in T2DM patients with high cardiovascular risk.[6–9]. Here, SLC5A2 is linked to type 2 diabetes mellitus.